Cost-consequence analysis of aprepitant compared to standard therapy (5-HT3 + corticosteroids) for the prevention of highly emetogenic chemotherapy-induced nausea and vomit:

Global & Regional Health Technology Assessment

RobertoRavasio¹ 

关键词: Aprepitant;    Chemotherapy-induced nausea;    vomiting (CINV);    Cost-consequence;    Highly emetogenic chemotherapy;   

DOI  :  10.5301/GRHTA.5000195

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

IntroductionPrevention of chemotherapy-induced nausea and vomiting (CINV) remains an important goal for patients receiving cytotoxic treatment. The objective of this study was to assess, from the Italian National Health Service payer perspective, the costs of an antiemetic regimen using aprepitant, a selective neurokinin-1 receptor antagonist, for patients receiving highly emetogenic chemotherapy.MethodsA decision-analytic model was developed to compare an aprepitant regimen (aprepitant, ondansetron, and dexamethasone) with a standard antiemetic regimen (ondansetron and dexamethasone) for expected costs after highly emetogenic chemotherapy. The model was populated with clinical results from patients treated with high-dose cisplatin in a randomized trial of CINV prevention therapy. Only direct medical costs (pharmacological treatment and emesis) – Euro 2014 – were considered. Sensitivity and threshold analyses on key clinical and economic parameters were performed.ResultsThe aprepitant regimen showed the l...

【 授权许可】

CC BY